76 Background: The benefits of Electronic Patient Remote Outcomes (e-PRO) for telemonitoring are well established, allowing early detection of illnesses and continuous monitoring of patients. We have previously shown high levels of compliance of use of telemonitoring in daily care. This new PROTECTY study assesses the predictive power of patient health status in the first month of treatment on survival, evaluated with the telemonitoring platform Cureety. Methods: This prospective study was conducted at the Military Hospital Bégin on prostate cancer patients. Patients were allowed to respond to a symptomatology questionnaire based on CTCAE v.5.0, personalized to their pathology and treatment. An algorithm evaluates the health status of the patient based on the reported adverse events, with a classification into 2 different states: Good Health status (A) Poor Health status (B) In case of A, the patient received therapeutic advice to help manage each of the reported adverse events. In case of B, the patient is invited to call the hospital. For the purpose of this analysis, we collected their health status during the first month after initiation of treatment. The primary endpoint was to assess if the first month health status is a predictive factor of progression free-survival (PFS) for prostate cancer patient. The secondary endpoint was to assess if the first month health status is a predictive factor of overall survival (OS) for prostate cancer patient. Results: Sixty-one patients were enrolled between July 1st, 2020 and June 30st, 2021. The median age was 74.0 (range 58.0 – 94.0). 62% presented a metastatic stage, and the most represented cancer was mHSPC with 39,5% among metastatic patients. Overall, 2443 questionnaires were completed by the patients, 4.0% resulted in a health classification in state B. 86,9% of patient were classified in group A the first month. 13,1% of patient were classified in group B the first month. The median follow up was 12.3 months. PFS at 12 months was 89% in A group vs 60% in B group, p=0,17 OS at 12 months was 100% in A group vs 86% in B group, p=0,15. Conclusions: Our study is the first to assess the impact of tolerance treatment on survival. The initial results suggest that e-PRO assessment by the platform could help identify in the early stages the patients that require further health assessment and potential therapeutic changes. While further follow-up of more patients will be required, our study highlights the importance of e-PRO in cancer patient care.